González-Recio, Irene
Simón, Jorge
Goikoetxea-Usandizaga, Naroa http://orcid.org/0000-0003-4569-028X
Serrano-Maciá, Marina http://orcid.org/0000-0003-4183-6384
Mercado-Gómez, Maria
Rodríguez-Agudo, Rubén http://orcid.org/0000-0001-5731-5052
Lachiondo-Ortega, Sofía http://orcid.org/0000-0003-1856-3664
Gil-Pitarch, Clàudia http://orcid.org/0000-0003-2220-0612
Fernández-Rodríguez, Carmen
Castellana, Donatello
Latasa, Maria U. http://orcid.org/0000-0002-0878-1337
Abecia, Leticia http://orcid.org/0000-0003-4097-8903
Anguita, Juan http://orcid.org/0000-0003-2061-7182
Delgado, Teresa C. http://orcid.org/0000-0001-9204-581X
Iruzubieta, Paula
Crespo, Javier http://orcid.org/0000-0001-8248-0172
Hardy, Serge
Petrov, Petar D. http://orcid.org/0000-0001-9697-4317
Jover, Ramiro http://orcid.org/0000-0002-4914-5804
Avila, Matías A. http://orcid.org/0000-0001-6570-3557
Martín, César
Schaeper, Ute http://orcid.org/0000-0003-2556-8391
Tremblay, Michel L. http://orcid.org/0000-0002-0281-541X
Dear, James W. http://orcid.org/0000-0002-8630-8625
Masson, Steven
McCain, Misti Vanette http://orcid.org/0000-0002-1967-0421
Reeves, Helen L. http://orcid.org/0000-0003-0359-9795
Andrade, Raul J. http://orcid.org/0000-0002-1565-0757
Lucena, M. Isabel http://orcid.org/0000-0001-9586-4896
Buccella, Daniela http://orcid.org/0000-0002-2266-9026
Martínez-Cruz, Luis Alfonso http://orcid.org/0000-0002-5856-9377
Martínez-Chantar, Maria L http://orcid.org/0000-0002-6446-9911
Funding for this research was provided by:
Ministerio de Economía y Competitividad (BFU2013-47531-R, BFU2016-77408-R)
Article History
Received: 30 April 2021
Accepted: 17 October 2022
First Online: 25 November 2022
Competing interests
: The rest of the authors declare no competing interest. U.S. is employed by Silence Therapeutics GmbH. This study is under the patent “Nucleic acids for inhibiting expression of Cnnm4 in a cell”. WO2021239825A1. Inventor: Ute Schaeper, Sibylle Dames, Steffen Schubert, Alfonso Martínez de la Cruz, Jorge Simón Espinosa, Irene González Recio, María Luz Martínez Chantar. (02/12/2021). The present patent previously described identifies the use of Galnac siRNA Cnnm4 for the treatment of liver disease. This article reinforces the validation of this therapeutic approach for the pathology of DILI due to paracetamol overdose.